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ABSTRACT 
Among the different type of route of administration oral route for drug administration is most common route in which Orodispersible tablet is 
preferred for the patient which are unconscious, week or for immediate control. The tablet gets dispersed in mouth cavity without water, 
present study deals with formulation of Naproxen sodium mouth dissolving tablets using super disintegrants. Naproxen sodium is analgesic 
and NSAID, used for the treatment of pain and inflammation caused by different condition such as osteoarthritis, rheumatoid arthritis and 
menstrual cramps. However gastric discomfort caused by naproxen sodium result in poor patient compliance associated with it conventional 
doses form but now days Naproxen sodium MDTs produces rapid onset of action and minimise gastric discomfort associated with it. Thus 
improves patient compliance, enhance bioavailability and reduces the dose of drug. MDTs are formulated by direct compression method using 
super disintegrants in different proportion. The powder blend is subjected to pre-compression evaluation parameters like bulk density, true 
density, and tapped density and angle of repose. Formulations are evaluated for weight variation, hardness, wetting time, water absorption 
time, disintegration time. And in vitro dissolution studies and all formulations complies Pharmacopoeias standards. The tablets are evaluated 
and result compared for all five formulation the most efficacious super disintegrants for MTDs of Naproxen sodium as suggested by the 
dispersion time, disintegration time and drug dissolution profiles.  
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I. INTRODUCTION: 
Naproxen Sodium is a non-steroidal anti-inflammatory 
agent useful for the treatment of pain inflammation and 
fever caused by the conditions such as arthritis, migraine 
and menstrual cramps. It has a good solubility in water and 
saliva and inherent ability to permeate through oral 
mucosal tissue, drug moiety is weak acidic so remains in 
partially none ionised form at oral Pᵸ which favour pre 
gastric absorption. These parameter makes the drug ideal 
character for MTD. These tablets display a fast and 
spontaneous de-aggregation in mouth, soon after the 
contact with saliva, the active agent can thus rapidly 
dissolved in the saliva and be absorbed through whatever 
membrane it encounters, during deglutition, unless it is 
protected from pre-gastric absorption. To fulfil these 
requirements tablets must be highly porous, incorporating 
hydrophilic excipients, able to rapidly absorb water for a 
rapid de-aggregation of the matrix. Different technological 
techniques, such as freeze drying, moulding and direct 
compression currently employed to prepare the 
formulation of this type present in the pharmaceutical 
market. The aim and objective of the present study is to 
develop and evaluate orodispersible tablet of Naproxen 
sodium and enhance the onset of action of Naproxen and 
also to study the influence of excipients on the physical 
characteristics of the tablets by applying two level three 
factor factorial designs taking Naproxen as model drug. 
2 MATERIALS AND METHODS 
2.1 API Structure Characterisation: 
Molecular Formula: C₁₄H₁₄O₃ 
Molecular mass: 230.26 
Melting point: 154⁰C to 158⁰C 
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State/ Form: White Powder. 
Description: Naproxen is an odourless, White to off white 
crystalline powder.  
Structure and IPUAC Name of Naproxen 
 
Chemical Name: (+)-2-(6-methoxy-2-naphthyl)-propionic 
acid. 
2.2 Pre formulation Study: 
Drug Solubility: As per research study from the Naproxen 
Sodium Wikipedia 
The Drug is soluble in lipid, practically insoluble in water 
at low pH and freely soluble in water at high pH. It is 
soluble in ethanol (95%) and in methanol. Solubility of 
drug in different solvent given in below table. 
S. No. Solvent Solubility 
1 Lipid Soluble 
2 Water Insoluble at low pH 
3 Water Freely Soluble at high pH 
4 Ethanol Soluble 
5 Methanol Soluble 
 
2.3 Drug and Excipients study: 
S. 
No. 
Drug + Excipient Duration 
(Months) 
Result 
1 Naproxen Sodium 6 Months Stable 
2 SSG 6 Months Stable 
3 CCS 6 Months Stable 
4 Cross povidone 6 Months Stable 
5 Aspartame 6 Months Stable 
6 Sodium CMC 6 Months Stable 
7 Mannitol 6 Months Stable 
8 Starch DC grade 6 Months Stable 
9 Magnesium stearate 6 Months Stable 
10 Talc 6 Months Stable 
11 Lactose 6 Months Stable 
12 MCC 6 Months Stable 
 
2.4 Material: Material and their use with obtained sources: 
S. No. Material Use of ingredients Sources 
1 Naproxen Sodium Active Ingredients Iosis Pharma 
2 Lactose Diluent  
 
 
Pacific India. 
 
A Pharmaceutical 
exporter, Village- Dhana, 
Bagbania Nalagarh, Solan, 
(H.P.) 
3 Microcrystalline cellulose Diluent 
4 SSG Disintegrants 
5 CCS Super Disintegrants 
6 Crospovidone Disintegrants 
7 Aspartame Diluents 
8 Sodium CMC Diluents 
9 Mannitol Diluents 
10 Starch DC grade Antiadhrants 
11 Magnesium stearate Glidant 
12 Talc Lubricants 
 
2.5 Preparation of Naproxen tablet by direct compression method: 
Formulation Table:  
Serial 
No. 
Ingredients C1  
(mg) 
C2  
(mg) 
C3 
 (mg) 
C4 
 (mg) 
C5 
 (mg) 
1 Naproxen Sodium 250 250 250 250 250 
2 SSG 9 9 9 9 9 
3 CCS      17.5 12.5 7.5 2.5 -- 
4 Crospovidone 9 9 9 9 9 
5 Lactose 9 9 9 9 9 
6 Aspartame 4.5 4.5 4.5 4.5 4.5 
7 Sodium CMC 9 9 9 9 9 
8 Mannitol 31 31 31 31 31 
9 Starch DC grade 36.5 41.5 46.5 51.5 53.5 
10 MCC 13 13 13 13 13 
11 Magnesium stearate 4.5 4.5 4.5 4.5 4.5 
12 Talc 7 7 7 7 7 
13 Total weight 400 400 400 400 400 
 
All the ingredients of formulation i.e. Active ingredients and 
additives were passed through 60 # sieve separately, 
Magnesium stearate and talc through 40 #, The ingredient 
were mixed by geometrical mixing and Tablet were 
compressed on 9 mm sizes of  biconvex round punch to get 
tablet by using Rimeck Single rotary compression machine. 
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3. Post compression parameters: 
3.1 Thickness of compressed tablets:  
The thickness of the compress tablets of Naproxen Sodium 
was determined using a Digital Vernier calliper. Ten tablets 
from each type of formulation were measure and average 
values were calculated in mm. 
3.2 Hardness: 
 The crushing strength of 10 tablets of each formulation was 
measured using Monsanto hardness tester and Pfizer 
harness tester. The tablet was hold along its oblong axis in 
Between the two jaws of the tester. At this point, reading 
should be zero kg/cm2. Then constant force was applied by 
rotating the knob in Monsanto tester and in case of Pfizer 
directly force applied until the tablet breakdown in the 
pieces. The reading the both cases at this point was noted. 
3.3 Friability Test: 
 Friability Test is generally used to measure of tablet 
strength. Roche Friability tester was used for testing the 
friability using. In This test subjects a number of compressed 
tablets to the combined effect of shock abrasion by utilizing 
a circular plastic chamber which revolves at a speed of 25 
revolutions per minutes for 4 minutes i.e. 100 rpm, dropping 
the compressed tablets to a distance of 6 inches in each 
revolution. A sample of Pre weighed 10 compressed tablets 
was placed in Roche friability chamber which was then 
operated for 100 revolutions i.e. 4 minutes. The tablets were 
then de-dusted and reweighed. A loss of less than 1 % in 
weight is generally considered and acceptable according to 
Pharmacopeia. Percentage friability (% F) was calculated as 
follows: 
% Friability = Initial Weight – Final Weight    X    100 
                                Initial Weight 
3.4 Weight variation test: 
As per the limitation of Pharmacopeia to find out weight 
variation test, 20 tablets of each type of formulation were 
weighed individually using single pan balance or an 
electronic balance, average weight was calculated and 
individual tablet weight was then compared with average 
value to find the deviation in weight. 
Specifications for tablets as per Indian pharmacopoeia 
1996: 
S. No. Average Weight of 
Tablet 
 (mg) 
Percentage  
Deviation 
1 80 mg or less 10 
2 More than 80 mg but less 
than 250 mg 
7.5 
3 250 mg or more 5 
3.5 Uniformity of Drug content:  
Five tablets of each compressed formulation are weighed 
and crushed in mortar Pastel and powdered, A quantity of 
powder equivalent to one tablets i.e. 450 mg was weighed 
and dissolved in 100 ml of 0.1 N Hydrochloric acid (pH 1.2). 
This was the stock solution from which 0.2 ml sample was 
withdraw and diluted to 10 ml with the help of 0.1N 
Hydrochloric acid. The drug content was estimated by 
recording the absorbance 272 nm by using UV- visible 
spectrophotometer. Content uniformity of the drug was 
calculated using formula. 
% Purity of the Drug = 10 C (Au / As) ------- 
Where, C = Concentration, 
Au and As=Absorbance’s obtained from unknown 
preparation and standard Preparation. 
3.6. Wetting time:  
This method is applied to calculate tablet wetting time. A 
piece of tissue paper or absorbent folded twice was placed in 
a small Glass Petri dish having the diameter 6.5 cm, 
containing 10 ml of water. Compressed tablet was placed on 
the paper, and the time record or note for complete wetting.  
Three trials for each batch were performed and standard 
deviation calculated. 
3.7. In vitro disintegration time: 
The process of breakdown or convert the tablet into pieces 
or into smaller particles is called as disintegration. The in 
vitro Disintegration time of a tablet was determined using 
disintegration test apparatus as per Indian Pharmacopeia 
specifications.  Place one tablet in each of the 6 tubes of the 
basket. Add a disc to each tube and run the apparatus using 
distilled water maintained at 37° ± 2°C which is similar to 
body temperature. The assembly should be raised and 
lowered between 30 cycles per minute in the 0.1 N HCL or 
Distilled water maintained at 37° ± 2°C. Time taken in 
second for complete disintegration of the tablet. In this 
disintegration test if the tablets are adhere to the 10 # sieve 
then continue the test till all tablets are completely 
disintegrated. 
3.8. In vitro dissolution test: 
Rate of dissolution are studied by using USP type-II 
apparatus having 50 rpm, using 900ml of 0.1 N Hydrochloric 
acid as dissolution solvent. Temperature of the dissolution 
medium was maintained at 37 ± 0.5°C. The sample of 
dissolution medium was withdrawn at every 5 min interval 
and first filtered. The absorbance of filtered solution was 
measured by using Ultra Violet spectro photometric method 
at 272 nm and concentration of the drug was determined 
from standard calibration curve. 
 
 
 
 
 
 
 
 
 
Ansari et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):462-468  
ISSN: 2250-1177                                                                                  [465]                                                                                 CODEN (USA): JDDTAO 
4. RESULT AND DISCUSSION:  
4.1 Pre compressed parameter and studies 
S. No. Formulation 
code 
Angle of Repose Bulk Density 
(Weight/ml) 
Taped Density 
(weight/ml) 
1 C1 28.78±0.45 0.46±0.02 0.49±0.02 
2 C2 29.92±0.70 0.45±0.02 0.48±0.04 
3 C3 28.40±0.69 0.44±0.03 0.47±0.02 
4 C4 27.36±0.63 0.43±0.03 0.49±0.04 
5 C5 26.10±0.56 0.42±0.02 0.47±0.02 
 
4.2 Post compression parameter Studies: 
Formulation 
code 
Hardness 
(Kg/cm2) 
Friability (%) Thickness 
(mm) 
Diameter 
(mm) 
Weight  
(mg) 
C1 5.8 0.45 4.02 9.01 410 
C2 6.2 0.62 4.05 9.02 396 
C3 5.6 0.32 3.98 9.02 405 
C4 6.4 0.48 4.01 9.03 398 
C5 6.2 0.75 3.99 9.02 406 
 
4.3 Post compression Studies: 
Formulation 
code 
Assay of Drug 
(%) 
Disintegration 
Time (Sec) 
Dissolution (%) Water Intake 
Time (Sec) 
C1 99.84 7 to 10 96.54 9 
C2 99.57 8 to 55 94.10 11 
C3 99.24 5 to 16 90.46 13 
C4 98.59 12 to 18 86.21 17 
C5 99.80 20 to 41 81.52 19 
 
4.4 Post compression studies of graphs: 
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4.4.1 Graph of C1 formulation: Naproxen 250 mg orodispersible tablet. 
```                                `  
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4.4.2 Graph of C2 formulation: Naproxen 250 mg orodispersible tablet. 
 
4.4.3 Graph of C3 formulation: Naproxen 250 mg orodispersible tablet. 
                                           
4.4.4 Graph of C4 formulation: Naproxen 250 mg orodispersible tablet. 
                                          
4.4.5 Graph of C5 formulation: Naproxen 250 mg orodispersible tablet 
                                        
Ansari et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):462-468  
ISSN: 2250-1177                                                                                  [468]                                                                                 CODEN (USA): JDDTAO 
5. CONCLUSION: 
After completion of this experiment the results obtained and 
conclude that development of orodispersible tablet of 
Naproxen sodium formulation by using super disintegrants 
i.e. Cross carmillose sodium gives the result of dissolution 
more than mentioned in the Pharmacopeia. Some results are 
mentioned below: 
1. Naproxen Sodium Active drug stable with different 
excipients. 
2. Fast Disintegrating tablets of Naproxen Sodium were 
successfully prepared by direct compression method. 
3. The flow property of the granules of three batches 
(C1,C3,C5) are better than two other formulation (C2,C4) 
and uniformity of the compressed tablets  are also better. 
4. The angle of repose of prepared granules are found less 
than 30º 
5. The hardness of compressed tablet by direct compression 
method found in the rage of 7.7 to 9.00 kg/cm2. 
6. The Thickness of the prepared tablets of all 5 formulations 
was found between 4.48 mm. to 4.55 mm. 
7. The Friability of the compressed tablet found within the 
range i.e. less than 1%. 
8. The in vitro disintegration studies are found to be in 7 to 
41 seconds. Formulation C1 show in vitro disintegration 
time i.e. 7-10 seconds. 
9. On the basis of disintegration time formulation C1 which 
facilitate the faster disintegration in the mouth. The in-vitro 
percentage drug releases from fast dissolving tablets of 
Naproxen Sodium prepared by direct compression method 
were found to be in the range of 100.47%. Hence, finally it 
was concluded that the   prepared orodispersible tablets of 
Naproxen Sodium 250 mg may prove to be potential 
candidate for effective fast disintegrating tablet dosage form. 
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